Since BCR::ABL1 testing was prompted by a suspected clinical diagnosis of CML rather than being performed routinely during the course of BCR::ABL1-negative MPN, the exact onset of secondary CML cannot be determined and may have occurred earlier than molecularly diagnosed. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.